134 related articles for article (PubMed ID: 11762416)
1. Monoclonal antibodies in the treatment of hematologic malignancies: radiation dosimetry aspects.
Stabin MG; Brill AB
Curr Pharm Biotechnol; 2001 Dec; 2(4):351-6. PubMed ID: 11762416
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
Wiseman GA; White CA; Stabin M; Dunn WL; Erwin W; Dahlbom M; Raubitschek A; Karvelis K; Schultheiss T; Witzig TE; Belanger R; Spies S; Silverman DH; Berlfein JR; Ding E; Grillo-López AJ
Eur J Nucl Med; 2000 Jul; 27(7):766-77. PubMed ID: 10952488
[TBL] [Abstract][Full Text] [Related]
3. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies.
Bartlett ML; Webb M; Durrant S; Morton AJ; Allison R; Macfarlane DJ
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1470-7. PubMed ID: 12397466
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging.
Stillebroer AB; Zegers CM; Boerman OC; Oosterwijk E; Mulders PF; O'Donoghue JA; Visser EP; Oyen WJ
J Nucl Med; 2012 Jan; 53(1):82-9. PubMed ID: 22159179
[TBL] [Abstract][Full Text] [Related]
5. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
6. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
Delaloye AB; Antonescu C; Louton T; Kuhlmann J; Hagenbeek A
J Nucl Med; 2009 Nov; 50(11):1837-43. PubMed ID: 19837764
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibody therapy of haematological malignancies.
Dearden C
BioDrugs; 2002; 16(4):283-301. PubMed ID: 12196040
[TBL] [Abstract][Full Text] [Related]
8. Hematologic Malignancies.
Tseng YD; Ng AK
Hematol Oncol Clin North Am; 2020 Feb; 34(1):127-142. PubMed ID: 31739939
[TBL] [Abstract][Full Text] [Related]
9. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma.
Wiseman GA; Leigh B; Erwin WD; Lamonica D; Kornmehl E; Spies SM; Silverman DH; Witzig TE; Sparks RB; White CA
Cancer; 2002 Feb; 94(4 Suppl):1349-57. PubMed ID: 11877765
[TBL] [Abstract][Full Text] [Related]
10. Biological dosimetry after total body irradiation (TBI) for hematologic malignancy patients.
Dossou J; Lartigau E; M'Kacher R; Légal JD; Bridier A; Guichard M; Eschwege F; Parmentier C
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):123-9. PubMed ID: 10656383
[TBL] [Abstract][Full Text] [Related]
11. Future of monoclonal antibodies in the treatment of hematologic malignancies.
Reff ME; Hariharan K; Braslawsky G
Cancer Control; 2002; 9(2):152-66. PubMed ID: 11965235
[TBL] [Abstract][Full Text] [Related]
12. Radiation dosimetry in nuclear medicine.
Stabin MG; Tagesson M; Thomas SR; Ljungberg M; Strand SE
Appl Radiat Isot; 1999 Jan; 50(1):73-87. PubMed ID: 10028629
[TBL] [Abstract][Full Text] [Related]
13. Antibodies and hematologic malignancies.
Smith MR
Cancer J; 2008; 14(3):184-90. PubMed ID: 18536558
[TBL] [Abstract][Full Text] [Related]
14. The clinical use of antibodies in haematological malignancies.
López-Guillermo A; Mercadal S
Ann Oncol; 2007 Jul; 18 Suppl 9():ix51-7. PubMed ID: 17631596
[No Abstract] [Full Text] [Related]
15. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
[TBL] [Abstract][Full Text] [Related]
16. Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era.
Klener P; Etrych T; Klener P
Curr Med Chem; 2019; 26(6):1002-1018. PubMed ID: 28990505
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
[TBL] [Abstract][Full Text] [Related]
18. Immune Modulation in Hematologic Malignancies.
Dhodapkar MV; Dhodapkar KM
Semin Oncol; 2015 Aug; 42(4):617-25. PubMed ID: 26320065
[TBL] [Abstract][Full Text] [Related]
19. Targeting Immune Checkpoints in Hematologic Malignancies.
Alatrash G; Daver N; Mittendorf EA
Pharmacol Rev; 2016 Oct; 68(4):1014-1025. PubMed ID: 27664133
[TBL] [Abstract][Full Text] [Related]
20. Evolving role of radiation therapy for hematologic malignancies.
Lee CK
Hematol Oncol Clin North Am; 2006 Apr; 20(2):471-503. PubMed ID: 16730303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
